Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical Trial
JAMA Oncol. 2024 May 9. doi: 10.1001/jamaoncol.2024.0938. Online ahead of print. ABSTRACT IMPORTANCE: Studies with nivolumab, an approved therapy for metastatic urothelial carcinoma (mUC) after …